Literature DB >> 2070704

Double-blind randomized multicenter study comparing Maalox TC tablets and ranitidine in healing of duodenal ulcers.

J O Hunter1, R J Walker, J Crowe, R R Gillies, K R Gillies, K R Gough, S Lorber.   

Abstract

The efficacy of ranitidine 150 mg twice daily and Maalox TC three tablets four times daily were compared in patients with endoscopically confirmed duodenal ulcer. Seventy-nine patients were randomly allocated to double-blind, double-dummy treatment, stratified for smokers. Endoscopy was repeated after four weeks. Those unhealed continued treatment for a further two weeks before final endoscopy. Per protocol analysis in 53 patients showed ulcer healing rates at week 4 and at weeks 4 and 6 combined of 78 and 89% on Maalox TC, and of 81 and 91% on ranitidine, respectively. The same analysis gave overall healing rates of 81% in smokers and 100% in nonsmokers, irrespective of treatment. Both treatments provided early ulcer pain relief. Diarrhea was a commoner side effect in patients on Maalox TC. The study showed Maalox TC and ranitidine were equally effective in healing duodenal ulceration.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2070704     DOI: 10.1007/BF01297140

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  10 in total

1.  Healing of duodenal ulcer with an antacid regimen.

Authors:  W L Peterson; R A Sturdevant; H D Frankl; C T Richardson; J I Isenberg; J D Elashoff; J Q Sones; R A Gross; R W McCallum; J S Fordtran
Journal:  N Engl J Med       Date:  1977-08-18       Impact factor: 91.245

2.  Antacid maintenance therapy in the prevention of duodenal ulcer relapse.

Authors:  K D Bardhan; J O Hunter; J P Miller; A B Thomson; D Y Graham; R I Russell; S Sontag; C Hines; T Martin; L Gaussen
Journal:  Gut       Date:  1988-12       Impact factor: 23.059

3.  Controlled therapeutic trial to determine the optimum dose of antacids in duodenal ulcer.

Authors:  N Kumar; J C Vij; A Karol; B S Anand
Journal:  Gut       Date:  1984-11       Impact factor: 23.059

4.  Cimetidine, cigarette smoking, and recurrence of duodenal ulcer.

Authors:  S Sontag; D Y Graham; A Belsito; J Weiss; A Farley; R Grunt; N Cohen; D Kinnear; W Davis; A Archambault
Journal:  N Engl J Med       Date:  1984-09-13       Impact factor: 91.245

5.  Gastric cytoprotection by antacids and papaverine in rats.

Authors:  J Hagel; H Renner; M Hirsch; G Weig; B Kaduk; H Ruppin; W Domschke
Journal:  Hepatogastroenterology       Date:  1982-12

6.  Medium-dose antacids versus cimetidine in the short-term treatment of duodenal ulcer.

Authors:  G Bianchi Porro; F Parente; M Lazzaroni; S Baroni; E Panza
Journal:  J Clin Gastroenterol       Date:  1986-04       Impact factor: 3.062

7.  Treatment of duodenal ulcer with low-dose antacids.

Authors:  G Lux; H Hentschel; H G Rohner; H Brunner; K Schütze; P C Lederer; W Rösch
Journal:  Scand J Gastroenterol       Date:  1986-11       Impact factor: 2.423

8.  Treatment of duodenal ulcer with antacid and sulpiride. A double-blind controlled study.

Authors:  S K Lam; K C Lam; C L Lai; C K Yeung; L Y Yam; W S Wong
Journal:  Gastroenterology       Date:  1979-02       Impact factor: 22.682

9.  Active smoking depresses prostaglandin synthesis in human gastric mucosa.

Authors:  G F Quimby; C A Bonnice; S H Burstein; G L Eastwood
Journal:  Ann Intern Med       Date:  1986-05       Impact factor: 25.391

10.  Duodenal ulcer healing with four antacid tablets daily.

Authors:  R Weberg; A Berstad; O Lange; T Schultz; E Aubert
Journal:  Scand J Gastroenterol       Date:  1985-11       Impact factor: 2.423

  10 in total
  2 in total

Review 1.  Antacids revisited: a review of their clinical pharmacology and recommended therapeutic use.

Authors:  P N Maton; M E Burton
Journal:  Drugs       Date:  1999-06       Impact factor: 9.546

2.  Can restrictions on reimbursement for anti-ulcer drugs decrease Medicaid pharmacy costs without increasing hospitalizations?

Authors:  D M Cromwell; E B Bass; E P Steinberg; Y Yasui; W J Ravich; T R Hendrix; S F McLeod; R D Moore
Journal:  Health Serv Res       Date:  1999-02       Impact factor: 3.402

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.